Morial Convention Center in New Orleans, LA. Two poster presentations include preclinical data that support the dosing regiment and study protocol for the subretinal clinical study for its lead ...

Two abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody ...

BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the McCormick Place Convention Center in Chicago, IL from ...

Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with ...

including two oral presentations, at the upcoming 28 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 13-17, 2025, in New Orleans, Louisiana. "We ...

today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company’s ...

Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to ...

will be highlighted in an oral presentation. In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic ...

"We are excited to build on our recent momentum of achieving full enrollment in our Phase 3 PROTECT study with a poster presentation at SCA 2025 that we can share with the global anesthesiologist ...

Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. Radiant’s ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference in Chicago, highlighting the safety and efficacy of its product, ADG126, an anti-CTLA-4 masking antibody, in combination ...